110 related articles for article (PubMed ID: 38750267)
1. Development of MKK4 inhibitors for liver regeneration.
Hindson J
Nat Rev Gastroenterol Hepatol; 2024 Jun; 21(6):376. PubMed ID: 38750267
[No Abstract] [Full Text] [Related]
2. Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration.
Pfaffenrot B; Klövekorn P; Juchum M; Selig R; Albrecht W; Zender L; Laufer SA
Eur J Med Chem; 2021 Jun; 218():113371. PubMed ID: 33794385
[TBL] [Abstract][Full Text] [Related]
3. From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4).
Klövekorn P; Pfaffenrot B; Juchum M; Selig R; Albrecht W; Zender L; Laufer SA
Eur J Med Chem; 2021 Jan; 210():112963. PubMed ID: 33199152
[TBL] [Abstract][Full Text] [Related]
4. Development of a non-radioactive, 384-well format assay to detect inhibitors of the mitogen-activated protein kinase kinase 4.
Togame H; Fuchikami K; Sagara A; Inbe H; Ziegelbauer K
Assay Drug Dev Technol; 2005 Feb; 3(1):65-76. PubMed ID: 15798397
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4.
Kircher T; Pantsar T; Oder A; Peter von Kries J; Juchum M; Pfaffenrot B; Kloevekorn P; Albrecht W; Selig R; Laufer S
Eur J Med Chem; 2021 Jan; 209():112901. PubMed ID: 33092905
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Covalent MKK4/7 Dual Inhibitor.
Jiang J; Jiang B; He Z; Ficarro SB; Che J; Marto JA; Gao Y; Zhang T; Gray NS
Cell Chem Biol; 2020 Dec; 27(12):1553-1560.e8. PubMed ID: 32916088
[TBL] [Abstract][Full Text] [Related]
7. MKK4 activates non-canonical NFκB signaling by promoting NFκB2-p100 processing.
Kim JS; Kim EJ; Kim HS; Kurie JM; Ahn YH
Biochem Biophys Res Commun; 2017 Sep; 491(2):337-342. PubMed ID: 28733031
[TBL] [Abstract][Full Text] [Related]
8. A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration.
Wuestefeld T; Pesic M; Rudalska R; Dauch D; Longerich T; Kang TW; Yevsa T; Heinzmann F; Hoenicke L; Hohmeyer A; Potapova A; Rittelmeier I; Jarek M; Geffers R; Scharfe M; Klawonn F; Schirmacher P; Malek NP; Ott M; Nordheim A; Vogel A; Manns MP; Zender L
Cell; 2013 Apr; 153(2):389-401. PubMed ID: 23582328
[TBL] [Abstract][Full Text] [Related]
9. MKK4 Inhibitors-Recent Development Status and Therapeutic Potential.
Katzengruber L; Sander P; Laufer S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108658
[TBL] [Abstract][Full Text] [Related]
10. First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure.
Zwirner S; Abu Rmilah AA; Klotz S; Pfaffenroth B; Kloevekorn P; Moschopoulou AA; Schuette S; Haag M; Selig R; Li K; Zhou W; Nelson E; Poso A; Chen H; Amiot B; Jia Y; Minshew A; Michalak G; Cui W; Rist E; Longerich T; Jung B; Felgendreff P; Trompak O; Premsrirut PK; Gries K; Muerdter TE; Heinkele G; Wuestefeld T; Shapiro D; Weissbach M; Koenigsrainer A; Sipos B; Ab E; Zacarias MO; Theisgen S; Gruenheit N; Biskup S; Schwab M; Albrecht W; Laufer S; Nyberg S; Zender L
Cell; 2024 Mar; 187(7):1666-1684.e26. PubMed ID: 38490194
[TBL] [Abstract][Full Text] [Related]
11. A Protoberberine derivative HWY336 selectively inhibits MKK4 and MKK7 in mammalian cells: the importance of activation loop on selectivity.
Kim N; Park J; Gadhe CG; Cho SJ; Oh Y; Kim D; Song K
PLoS One; 2014; 9(4):e91037. PubMed ID: 24759688
[TBL] [Abstract][Full Text] [Related]
12. Myricetin attenuated MPP(+)-induced cytotoxicity by anti-oxidation and inhibition of MKK4 and JNK activation in MES23.5 cells.
Zhang K; Ma Z; Wang J; Xie A; Xie J
Neuropharmacology; 2011; 61(1-2):329-35. PubMed ID: 21549720
[TBL] [Abstract][Full Text] [Related]
13. Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.
Chen D; Wang W; Qin JJ; Wang MH; Murugesan S; Nadkarni DH; Velu SE; Wang H; Zhang R
Curr Cancer Drug Targets; 2013 Jul; 13(6):651-60. PubMed ID: 23607596
[TBL] [Abstract][Full Text] [Related]
14. Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration.
Tsugawa D; Oya Y; Masuzaki R; Ray K; Engers DW; Dib M; Do N; Kuramitsu K; Ho K; Frist A; Yu PB; Bloch KD; Lindsley CW; Hopkins CR; Hong CC; Karp SJ
J Pharmacol Exp Ther; 2014 Dec; 351(3):549-58. PubMed ID: 25271257
[TBL] [Abstract][Full Text] [Related]
15. Requirements for PKC-augmented JNK activation by MKK4/7.
Lopez-Bergami P; Ronai Z
Int J Biochem Cell Biol; 2008; 40(5):1055-64. PubMed ID: 18182317
[TBL] [Abstract][Full Text] [Related]
16. Functional and clinicopathological analysis of loss of MKK4 expression in endometrial cancer.
Ishikawa M; Nakayama K; Rahman MT; Rahman M; Katagiri A; Iida K; Miyazaki K
Oncology; 2010; 79(3-4):238-46. PubMed ID: 21372598
[TBL] [Abstract][Full Text] [Related]
17. Astrocyte-Derived Exosomal microRNA miR-200a-3p Prevents MPP
Shakespear N; Ogura M; Yamaki J; Homma Y
Neurochem Res; 2020 May; 45(5):1020-1033. PubMed ID: 32016794
[TBL] [Abstract][Full Text] [Related]
18. Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors.
Juchum M; Pfaffenrot B; Klövekorn P; Selig R; Albrecht W; Zender L; Laufer SA
Eur J Med Chem; 2022 Oct; 240():114584. PubMed ID: 35868124
[TBL] [Abstract][Full Text] [Related]
19. Covalent JNK inhibitors?
Borhani DW
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):E18; author reply E19. PubMed ID: 19204298
[No Abstract] [Full Text] [Related]
20. Novel screening cascade identifies MKK4 as key kinase regulating Tau phosphorylation at Ser422.
Grueninger F; Bohrmann B; Christensen K; Graf M; Roth D; Czech C
Mol Cell Biochem; 2011 Nov; 357(1-2):199-207. PubMed ID: 21638028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
